Product Description

🔹 Product Overview
EMGRAST 300 Injection is a prescription hematopoietic growth factor medicine used to prevent and manage neutropenia (low white blood cell count), especially in patients receiving chemotherapy, bone marrow transplantation, or certain treatments that reduce immune cell levels. It contains Filgrastim 300 mcg, a Granulocyte Colony-Stimulating Factor (G-CSF) that stimulates the bone marrow to produce more neutrophils, which help the body fight infections.
EMGRAST 300 Injection is administered by a healthcare professional and requires monitoring of blood cell counts during treatment.

🔹 Key Uses
EMGRAST 300 Injection may be prescribed for:
Prevention of infection due to chemotherapy-induced neutropenia
Reduction of risk of febrile neutropenia
Recovery of white blood cell counts after cancer treatment
Neutropenia associated with bone marrow transplantation
Certain chronic neutropenia conditions
Increasing stem cell mobilization before collection procedures (as advised by specialists)

🔹 Composition
Active Ingredient:
Filgrastim 300 mcg
Drug Class:
Granulocyte Colony-Stimulating Factor (G-CSF)
Hematopoietic Growth Factor
Therapeutic Class:
Anti-neoplastic supportive therapy
Neutropenia management medicine
Dosage Form:
Injectable solution

🔹 How It Works
EMGRAST 300 contains Filgrastim, which acts similar to the body's natural G-CSF hormone.
It works by:
Stimulating the bone marrow to produce neutrophils
Increasing the release of infection-fighting white blood cells into circulation
Helping reduce the duration and severity of neutropenia
This improves the body's ability to fight bacterial and other infections during periods when immunity is weakened.

🔹 Key Benefits
Helps increase neutrophil production
Reduces infection risk during chemotherapy
Supports immune system recovery after cancer treatments
Helps maintain planned chemotherapy schedules
Provides targeted support for patients with low white blood cell counts
Used as part of specialist-guided supportive care

🔹 Dosage and Administration
Use only under the supervision of an oncologist or healthcare professional.
EMGRAST 300 Injection is usually given by:
Subcutaneous injection (under the skin), or
Intravenous administration when required
Dose and duration depend on:
Type of treatment received
Neutrophil count
Patient response
Overall medical condition
Regular blood tests may be required to monitor white blood cell levels during therapy.

🔹 Possible Side Effects
Common side effects may include:
Bone pain
Headache
Weakness
Injection site pain or redness
Muscle or joint discomfort
Nausea
Fever
Serious side effects requiring medical attention may include:
Severe allergic reactions
Difficulty breathing
Sudden severe abdominal or left shoulder pain (possible spleen-related complications)
Unusual swelling or severe discomfort

🔹 Precautions
Before receiving EMGRAST 300 Injection:
Inform your doctor about any allergies.
Tell your doctor if you have spleen problems or blood disorders.
Inform your healthcare provider about all medicines being taken.
Regular blood monitoring is important during treatment.
Do not use without medical supervision.
Report unusual pain, fever, or breathing difficulties immediately.